Internal Medicine, Hematology & Oncology · Harrisburg, PA
NPI
1588755904
Since 2006
Specialty
Internal Medicine, Hematology & Oncology
Code 207RH0003X
Group practices
2
Medicare group memberships
Hospitals
5
Hospital affiliations
4300 Londonderry Rd Ste 302
Harrisburg, PA, 17109
Phone (717) 724-6780
Groups this clinician bills Medicare through
Medicare paid, 2024
$97K
1,231 services
Medicare patients, 2024
178
Average age 70
Drug cost, 2024
$11.9M
2,598 prescriptions
Company payments, 2025
$580K
From 21 companies
Procedures and visits billed to Original Medicare, 2024
In 2024, the most common Medicare service billed by Salman Fazal was code 99215 (office e&m - established), 334 times for 92 patients. In total Salman Fazal billed 1,231 services in 24 codes, and Medicare paid $97K.
| Code |
|---|
Official US government data: the national provider registry and Medicare enrollment records, linked by NPI. Last update of this record: 2026-02-13.
| Setting |
|---|
| Services |
|---|
| Patients |
|---|
| Paid per service |
|---|
| Medicare paid |
|---|
| 99215 Office E&M - Established | Office | 334 | 92 | $126.09 | $42K |
| G2211 Visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's | Office | 329 | 100 | $11.66 | $3,836 |
| 99233 Hospital E&M - Subsequent | Facility | 310 | 73 | $90.48 | $28K |
| 99214 Office E&M - Established | Office | 114 | 69 | $88.92 | $10K |
| 99223 Hospital E&M - Initial | Facility | 31 | 26 | $131.71 | $4,083 |
| 99232 Hospital E&M - Subsequent | Facility | 25 | 11 | $61.63 | $1,541 |
| 99239 Hospital Discharge Management | Facility | 24 | 21 | $89.32 | $2,144 |
| 99205 Office E&M - New | Office | 15 | 15 | $157.50 | $2,363 |
By year: 2022 $78K for 858 services; 2023 $71K for 729 services; 2024 $97K for 1,231 services.
Medicare prescription drug claims, 2024
In 2024, the drug Salman Fazal prescribed most often to Medicare patients was Acyclovir, with 378 prescriptions and refills. In total Salman Fazal wrote 2,598 Medicare prescriptions that cost $11.9M.
| Drug | Claims | 30-day fills | Patients | Cost |
|---|---|---|---|---|
| Acyclovir Generic | 378 | 538 | 72 | $5,191 |
| Jakafi Ruxolitinib Phosphate | 212 | 212 | 28 | $3.4M |
| Sulfamethoxazole-Trimethoprim Sulfamethoxazole/Trimethoprim | 118 | 132 | 24 | $303 |
| Ciprofloxacin Hcl Generic | 117 | 141 | 32 | $1,963 |
| Venclexta Venetoclax | 114 | 116 | 33 | $383K |
| Voriconazole Generic | 109 | 121 | 19 | $47K |
| Atovaquone Generic | 76 | 82 | Under 11 | $48K |
| Ojjaara Momelotinib Dihydrochloride | 49 | 49 | Under 11 | $1.3M |
| Pantoprazole Sodium Generic | 45 | 67 | 13 | $347 |
| Famotidine Generic | 45 | 59 | Under 11 | $398 |
| Eliquis Apixaban | 42 | 52 | Under 11 | $28K |
| Allopurinol Generic | 41 | 53 | 12 | $261 |
| Ondansetron Hcl Generic | 39 | 45 | 21 | $357 |
| Oxycodone Hcl Generic | 38 | 38 | 14 | $592 |
| Hydroxyurea Generic | 37 | 61 | Under 11 | $178 |
Brand drugs: - claims; generic drugs: 1,738 claims; opioid claims: 68.
Money and other things of value reported by the companies
In 2025, drug and medical device companies paid Salman Fazal $580K ($580K in general payments such as food, travel and fees) from 21 companies. The largest payer was Incyte Corporation with $109K.
| Company | Payments | Amount |
|---|---|---|
| Incyte Corporation INCY | 118 | $109K |
| Taiho Oncology, Inc. 4578.T | 48 | $67K |
| GlaxoSmithKline, LLC. GSK | 21 | $55K |
| Syndax Pharmaceuticals, Inc. SNDX | 27 | $52K |
| Blueprint Medicines Corporation SNY | 37 | $49K |
| Janssen Biotech, Inc. JNJ | 43 | $47K |
| Sobi, Inc SOBI.ST | 28 | $44K |
| Sanofi US Services Inc. SNY | 25 | $33K |
| Sanofi-Aventis U.S. LLC SNY | 10 | $25K |
| Stemline Therapeutics Inc. | 12 | $23K |
Official US government data on Original Medicare services, Medicare prescription drug plans and the payments drug and device companies must report. Services with fewer than 11 patients and drugs with fewer than 11 claims are not published. Procedure codes are shown by number with their public category.